Homozygous Deletions in AHNAK2 as an Unexpected Genetic Cause of Polyneuropathy (P12-11.019) [0.03%]
AHNAK2纯合子缺失作为周围神经病变的遗传病因（P12-11.019）
Nicholas Mallett,Rachel Green,Christopher Lee
Nicholas Mallett
Objective: To provide a case review of a patient with a rare, genetic cause of polyneuropathy. Background: Since the advent of whole ge...
Headache in a Case of Tuberculosis: Think Beyond Meningitis (P11-12.006) [0.03%]
结核病患者的头痛 症状不要只考虑脑膜炎(P11-12.006)
Varun Singh,Sanchit Chouksey,Rameshwar Chaurasia et al.
Varun Singh et al.
Objective: NA. Background: Intracranial hypertension may be primary (idiopathic) or secondary to some underlying conditions like intrac...
Early-stage Parkinson's Disease Experiences with a Week-long Dopaminergic Medication Washout (P4-5.028) [0.03%]
早期帕金森病患者使用多巴胺能药物一周的清洗期体验
Kian Pazira,Liliana Venditti,Kemberlee Bonnet et al.
Kian Pazira et al.
Objective: To describe early-stage Parkinson's disease (PD) experiences when completing a one-week washout of dopaminergic medications. Background: ...
Personalized Alzheimer's Risk Reduction Software Improves Calculated Alzheimer's Risk: A Digital, Decentralized, Randomized Controlled Trial (P1-3.004) [0.03%]
个性化阿尔茨海默病风险降低软件可改善计算出的阿尔茨海默病风险：一项数字去中心化随机对照试验
Richard Isaacson,Jennifer Reschke,Mark McInnis et al.
Richard Isaacson et al.
Objective: To determine the efficacy of automated digital health risk reduction software compared to a time-neutral control in lowering calculated Alzheimer's risk. ...
Randomized Controlled Trial
Neurology. 2025 Apr 8;104(7_Supplement_1):2493. DOI:10.1212/WNL.0000000000210376 2025
A Pilot Survey Into the Landscape of Neuro-oncology Care in the Community (P3-6.003) [0.03%]
社区神经肿瘤学护理状况的试点调查(P3-6.003)
Christine Lu-Emerson,Sajeel Chowdhary,Rupesh Kotecha et al.
Christine Lu-Emerson et al.
Objective: The objective of this study was to understand the current landscape of the delivery of neuro-oncology care in the community. Importantly, the goal was to highlight challenges faced by community partners and to ...
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile from the OCARINA II Study and Patient Preferences (P8-1.003) [0.03%]
奥马珠单抗皮下注射：来自OCARINA II研究的疗效和安全性特征的进一步描述以及患者偏好（P8-1.003）
Scott Newsome,Lawrence Goldstick,Krzysztof Selmaj et al.
Scott Newsome et al.
Objective: To further characterize the benefit-risk profile of ocrelizumab (OCR) subcutaneous (SC) based on updated efficacy/safety data, and new patient-reported outcomes (PROs) from OCARINA II (NCT05232825), at the clin...
Randomized Controlled Trial
Neurology. 2025 Apr 8;104(7_Supplement_1):2494. DOI:10.1212/WNL.0000000000210377 2025
Acute Brachial Diplegia: An Unusual Presentation of West Nile Virus Encephalomyelitis (P2-10.002) [0.03%]
急性上肢重瘫：西尼罗河病毒脑脊髓炎的不常见表现(P2-10.002)
Lior Zweig,Nikhita Shrimanker,Richard Fagbemigun et al.
Lior Zweig et al.
Objective: NA. Background: West Nile Virus (WNV) encephalomyelitis is a mosquito-borne illness, now endemic to the Northeast United Sta...
A Rare Case of Spinal Cord Compression Due to Thoracic Arachnoid Cyst in a 47-Year-Old Woman (P3-14.005) [0.03%]
一例47岁女性胸腔蛛网膜囊肿脊髓压迫症患者病例报告(P3-14.005)
Anika Zahoor,Subtain Ali,Dhairya Lakhani et al.
Anika Zahoor et al.
Objective: To emphasize the importance of timely intervention for treating thoracic arachnoid cysts to achieve immediate relief of neurological deficits. ...
Alexander's Other Law: Leo Alexander and the Nuremberg Code (P5-11.001) [0.03%]
亚历山大其他法则：莱奥·亚历山大与纽伦堡法典(第五部分)
Stephen Ronay,Rachel Belfer,Neil A Busis
Stephen Ronay
Objective: To highlight neurologist and psychiatrist Leo Alexander's contributions to advancing ethical medical research on human subjects. Background: ...
A Case of Aicardi Syndrome with Positive Outcomes Following Hemispherectomy (P10-9.015) [0.03%]
Callosal-Agnosia-Ocular-Movement-Handicap综合症伴半球切除术后良好预后的病例报告
Ann Zheng,Simona Proteasa
Ann Zheng
Objective: To highlight a case of Aicardi Syndrome in a patient with improved seizure control after undergoing hemispherectomy. Background: ...